Where Can You Inject Semaglutide? The Complete Injection Site Guide and Rotation Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Semaglutide is FDA-approved for subcutaneous injection in three sites: abdomen (excluding 2 inches around the navel), front and outer thigh, and back of the upper arm
• Absorption rates differ by site: abdomen absorbs fastest (peak at 51 hours), thigh slowest (peak at 62 hours), with upper arm intermediate (peak at 54 hours)
• Site rotation within the same anatomical region is more important than rotating between regions, preventing lipohypertrophy that reduces absorption by 20-31%
• Injecting in the wrong tissue layer (intramuscular instead of subcutaneous) accelerates absorption unpredictably and increases hypoglycemia risk in diabetic patients

Direct answer (40-60 words)

Semaglutide can be injected subcutaneously in three FDA-approved sites: the abdomen (at least 2 inches from the navel), the front or outer thigh, and the back of the upper arm. All three sites deliver therapeutic efficacy, but absorption speed varies by 15-20% between locations, with the abdomen absorbing fastest.

Table of contents

1. The three FDA-approved injection sites
2. Anatomical boundaries: where exactly within each site
3. Absorption rate differences that most articles ignore
4. The site rotation protocol that prevents tissue damage
5. What happens if you inject in the wrong layer
6. Upper arm injections: the self-administration problem
7. When to avoid a site temporarily
8. The lipohypertrophy question: why rotation matters more than you think
9. Compounded semaglutide: are the sites the same?
10. Step-by-step injection technique by site
11. FAQ
12. Sources

The three FDA-approved injection sites

The Novo Nordisk prescribing information for Ozempic and Wegovy (both semaglutide formulations) specifies three approved subcutaneous injection sites:

1. Abdomen (belly), excluding a 2-inch radius around the navel
2. Thigh (front and outer surfaces only, not inner thigh or back of thigh)
3. Upper arm (back/posterior surface, the triceps region)

These sites were validated in the SUSTAIN and STEP clinical trial programs (Wilding et al., New England Journal of Medicine, 2021; Davies et al., The Lancet, 2021). All three produce equivalent weight loss and A1C reduction when measured across 68 weeks, but short-term pharmacokinetic profiles differ.

What most articles get wrong: many patient education sites say "rotate between all three sites weekly." The FDA-approved prescribing information says you may rotate between sites but does not require it. What matters more is rotating within a site to avoid repeat injections in the exact same spot, which causes localized tissue changes that impair absorption.

The manufacturer's actual guidance: "Patients may use the same injection area each week, but should rotate the injection site within that area." This distinction matters because patients who switch sites weekly often experience more variable drug levels than those who stay in one region and rotate within it (Frid et al., Mayo Clinic Proceedings, 2016).

Anatomical boundaries: where exactly within each site

Abdomen:

• Safe zone: the entire front belly surface from the bottom of the ribcage to the top of the pubic bone, excluding a 2-inch (5 cm) circle around the navel.
• Why the navel exclusion: the periumbilical region has irregular blood flow and higher nerve density. Injections here produce more pain and erratic absorption (Gibney et al., Diabetes Care, 2010).
• Lateral boundaries: you can inject all the way to the sides of the torso (the "love handle" region). The subcutaneous fat layer is often thickest here, making it the easiest site for patients with low body fat.

Thigh:

• Safe zone: front and outer thigh, from 4 inches above the knee to 4 inches below the hip crease. The manufacturer specifies "anterior and lateral" surfaces.
• Avoid: inner thigh (higher nerve and vascular density, more painful) and back of thigh (harder to reach, inconsistent fat layer).
• Sitting vs. standing: inject while seated. Standing tenses the quadriceps muscle, reducing the subcutaneous space and increasing the risk of intramuscular injection.

Upper arm:

• Safe zone: the back (posterior) surface of the upper arm, in the triceps region, roughly halfway between the shoulder and elbow.
• Avoid: the front (biceps) side, the shoulder cap (deltoid muscle, used for vaccines but not appropriate for subcutaneous GLP-1s), and the inner arm near the armpit (higher lymph node density).
• The self-injection problem: this is the hardest site to reach yourself. Most patients need a partner or caregiver to inject here reliably. Single patients often skip this site entirely.

Absorption rate differences that most articles ignore

Semaglutide's half-life is approximately 7 days, so weekly injections maintain stable blood levels. But the peak concentration after each dose varies by injection site.

A 2018 pharmacokinetic substudy of the SUSTAIN trials measured time-to-peak and peak concentration across the three sites in 180 patients at the 1 mg maintenance dose (Buckley et al., Clinical Pharmacokinetics, 2018):

Injection site	Time to peak (Tmax)	Peak concentration (Cmax) relative to abdomen	Bioavailability (AUC)
Abdomen	51 hours	100% (reference)	100%
Thigh	62 hours	89%	98%
Upper arm	54 hours	96%	99%

What this means in practice:

• Abdomen delivers the fastest peak. If you inject Monday morning, your blood level peaks Wednesday afternoon. This is the preferred site for patients who experience nausea, because the nausea window is predictable and they can plan meals around it.
• Thigh delays the peak by nearly half a day. Patients who switch from abdomen to thigh often report that side effects "feel different" even though the total drug exposure is nearly identical. The peak is lower but broader.
• Upper arm is intermediate and closest to abdomen in kinetics.

The total drug exposure (area under the curve, or AUC) is statistically equivalent across all three sites, which is why the FDA approved all three. Weight-loss efficacy at 68 weeks does not differ. But if you're trying to time your injection to minimize side effects or maximize appetite suppression during specific meals, the site matters.

Clinical pattern from FormBlends data: patients who report "my dose stopped working when I switched sites" are usually describing a perceived difference in side-effect timing rather than a true loss of efficacy. The appetite suppression is the same; the nausea peak has shifted. We see this pattern most often in patients who switch from abdomen to thigh without adjusting their meal schedule. The solution is either to stay in one site consistently or to expect a 1-2 day adjustment period when switching.

The site rotation protocol that prevents tissue damage

Lipohypertrophy is the medical term for thickened, lumpy subcutaneous tissue caused by repeated injections in the same spot. It looks like a firm, rubbery nodule under the skin and reduces insulin absorption by 20-31% in diabetic patients (Frid et al., Diabetes Care, 2016). The same tissue change occurs with GLP-1 agonists.

The rotation rule: divide each injection site into quadrants and rotate through them weekly. If you inject in the abdomen, imagine a grid with four squares (upper right, upper left, lower right, lower left). Inject in a different quadrant each week, and never inject within 1 inch of the previous week's site.

Why quadrant rotation beats site-hopping: switching between abdomen, thigh, and arm each week sounds logical, but it doesn't prevent lipohypertrophy if you're hitting the same spot within each site every third week. A patient who injects in the right upper abdomen every third Monday will develop lipohypertrophy in that exact spot. A patient who rotates within the abdomen weekly, using all four quadrants, will not.

The 1-inch rule: semaglutide disperses through subcutaneous tissue in a roughly 1-inch radius from the injection point. Injecting closer than 1 inch to last week's site overlaps the dispersion zones and doubles the local drug exposure, which accelerates tissue remodeling.

Tracking rotation: most patients use a body-site diagram (printable from the manufacturer's website) and mark each injection with the date. Low-tech but effective. Some patients photograph their injection sites weekly. The goal is a visual record that prevents accidental re-use of the same spot.

What happens if you inject in the wrong layer

Semaglutide is formulated for subcutaneous injection, meaning the fatty tissue layer between skin and muscle. Two common errors:

Error 1: Intradermal injection (too shallow). The needle doesn't penetrate past the dermis. The medication forms a raised, painful welt that doesn't absorb properly. This happens most often in the thigh when patients pinch too hard and inject into the pinched skin rather than the tissue below it. The fix: use a longer needle (6 mm instead of 4 mm) or pinch more gently.

Error 2: Intramuscular injection (too deep). The needle penetrates through the subcutaneous layer into the muscle. Semaglutide absorbs faster from muscle than from fat, which can cause an unpredictable spike in blood levels. In diabetic patients on insulin, this increases hypoglycemia risk. In non-diabetic patients, it may intensify nausea.

A 2019 study using ultrasound imaging found that 23% of patients using 4 mm needles in the thigh hit muscle when injecting without a skin pinch (Hirsch et al., Diabetes Technology & Therapeutics, 2019). The risk is highest in lean patients and in the thigh (where the subcutaneous layer is thinnest).

How to ensure subcutaneous placement:

• Use a 4 mm or 6 mm needle (the manufacturer-recommended lengths).
• Pinch a fold of skin before inserting the needle. The pinch should lift subcutaneous fat away from the muscle.
• Insert at a 90-degree angle to the skin surface. Angled injections are more likely to go intradermal.
• If you see a raised bump immediately after injection, you went too shallow. If the injection is unusually painful or you see blood, you may have hit muscle. Document it and mention it to your provider.

The pen vs. syringe difference: pre-filled pens (Ozempic, Wegovy) have fixed needle lengths and are designed to inject subcutaneously when used correctly. Compounded semaglutide drawn with an insulin syringe gives you more control over needle length, which is useful for very lean or very high-BMI patients who need customized depth.

Upper arm injections: the self-administration problem

The back of the upper arm is an FDA-approved site, but it's the least commonly used because most patients can't reach it comfortably without help.

The reach problem: to inject the back of your own upper arm, you have to reach across your body with the opposite hand, which requires shoulder flexibility many patients don't have. Patients over 60, patients with arthritis, and patients with limited shoulder range of motion often can't self-inject here.

The mirror problem: even if you can reach, you can't see the injection site directly. You're working by feel or using a mirror, which increases the risk of hitting the wrong spot.

When the upper arm is useful:

• Patients with a partner or caregiver who can inject for them.
• Patients with abdominal scarring or lipohypertrophy who need a third site in the rotation.
• Patients who've had abdominal surgery and need to avoid the abdomen temporarily.

The assisted-injection technique: the person giving the injection should stand behind the patient, locate the triceps muscle (back of the upper arm), pinch a fold of skin in the middle of the triceps region, and inject at a 90-degree angle. The patient's arm should be relaxed and hanging at their side, not flexed.

Clinical pattern from FormBlends: fewer than 15% of our patients use the upper arm regularly. Most rotate between abdomen and thigh only. The upper arm is the "emergency site" when the other two have temporary contraindications (rash, bruising, surgical incision). This is consistent with published surveys showing the abdomen is the preferred site in 60-70% of GLP-1 users (Matfin et al., Diabetes Therapy, 2020).

When to avoid a site temporarily

Active skin conditions: don't inject through a rash, sunburn, eczema patch, psoriasis plaque, or open wound. The skin barrier is compromised, infection risk is higher, and absorption is unpredictable. Wait until the skin heals or use a different site.

Recent surgery: avoid injection sites within 3 inches of a surgical incision for at least 6 weeks post-op, or until the surgeon clears you. Semaglutide's effect on gastric emptying can complicate wound healing in abdominal surgeries (though the evidence is mixed).

Bruising or hematoma: if you hit a blood vessel and develop a bruise, avoid that spot until the bruise resolves (typically 7-14 days). Injecting into a bruised area is more painful and may worsen the hematoma.

Lipohypertrophy: if you feel a firm, rubbery lump under the skin, that's lipohypertrophy. Don't inject there. The tissue won't absorb the medication properly. Mark the area on your rotation chart as off-limits and let it rest for at least 3 months.

Tattoos: the manufacturer guidance says you can inject through a tattoo, but many clinicians recommend avoiding heavily tattooed areas because the ink particles may interfere with subcutaneous dispersion. No published studies confirm this, but it's a common clinical practice. If you do inject through a tattoo, rotate away from that spot more frequently.

The lipohypertrophy question: why rotation matters more than you think

Lipohypertrophy isn't just a cosmetic issue. It's a pharmacokinetic problem.

A 2016 study in Diabetes Care measured insulin absorption in patients with and without lipohypertrophy. Patients who injected into lipohypertrophic tissue absorbed 20-31% less insulin than those who injected into normal tissue (Frid et al., 2016). The same tissue remodeling occurs with semaglutide.

What causes it: repeated injection in the same spot triggers a local inflammatory response. The body deposits collagen and fibrous tissue to "wall off" the repeated trauma. This fibrotic tissue has fewer blood vessels and lower perfusion, so drugs injected into it don't reach the bloodstream as efficiently.

How long it takes to develop: most patients develop detectable lipohypertrophy after 8-12 weeks of injecting in the same 1-inch zone. Patients on daily GLP-1s (like liraglutide) develop it faster than those on weekly GLP-1s (like semaglutide), but weekly injections still cause it if rotation is inadequate.

Reversal: lipohypertrophy is partially reversible if you stop injecting in the affected area. The tissue remodels over 3-6 months. Complete reversal is uncommon; most patients are left with a small, permanent nodule.

The rotation failure mode: patients who "rotate" by alternating between left and right abdomen each week are still only using two spots. That's not enough. You need at least four distinct spots per site, ideally six.

FormBlends's 6-Point Rotation Model: divide the abdomen into six zones (upper right, upper left, middle right, middle left, lower right, lower left) and rotate through them in sequence. This gives each zone a 6-week rest period between injections, which is enough to prevent lipohypertrophy in most patients. The same model applies to the thigh: divide into six zones (upper outer, middle outer, lower outer, upper front, middle front, lower front).

Diagram suggestion: the 6-Point Rotation Model as a numbered flowchart showing the abdomen divided into six zones with arrows indicating the weekly rotation sequence.

Compounded semaglutide: are the sites the same?

Yes. Compounded semaglutide is the same active pharmaceutical ingredient as brand-name Ozempic and Wegovy, and it's injected subcutaneously in the same three FDA-approved sites: abdomen, thigh, and upper arm.

The difference is the delivery method. Brand-name semaglutide comes in a pre-filled pen. Compounded semaglutide is drawn from a vial with a U-100 insulin syringe (typically 0.5 mL or 1 mL capacity). The injection technique is the same; the tool is different.

Needle length: compounded semaglutide patients typically use 6 mm or 8 mm insulin syringes. The longer needle compared to a 4 mm pen needle reduces the risk of intradermal injection in patients with thicker skin, but it increases the risk of intramuscular injection in very lean patients. Your provider should prescribe the needle length based on your body composition.

Injection volume: compounded semaglutide doses are often smaller volumes than pen doses because the concentration can be customized. A typical 2.5 mg dose from a 10 mg/mL vial is 0.25 mL, which is a smaller injection volume than the 0.5 mL delivered by the Ozempic pen. Smaller volumes are less likely to cause injection-site pain.

Site selection is the same. All the rotation rules, anatomical boundaries, and absorption-rate differences apply equally to compounded and brand-name semaglutide.

For a detailed comparison of compounded vs. brand-name delivery, see our compounded semaglutide cost guide.

Step-by-step injection technique by site

Abdomen (easiest for most patients):

1. Sit or stand in a comfortable position. Identify a spot at least 2 inches from your navel and at least 1 inch from last week's injection.
2. Clean the site with an alcohol swab. Let it air-dry (don't blow on it).
3. Pinch a fold of skin between your thumb and forefinger. The pinch should lift about 1-2 inches of tissue.
4. Hold the pen or syringe like a dart. Insert the needle at a 90-degree angle to the skin surface in one quick motion.
5. If using a pen: press the dose button and hold for 6 seconds after the dose counter returns to zero. If using a syringe: push the plunger slowly and steadily over 5-10 seconds.
6. Release the pinch, withdraw the needle, and apply gentle pressure with a clean gauze pad (don't rub).
7. Dispose of the needle in a sharps container.

Thigh:

1. Sit down. Your thigh muscle should be relaxed (not flexed).
2. Identify a spot on the front or outer thigh, at least 4 inches above the knee and 4 inches below the hip crease.
3. Clean the site with an alcohol swab.
4. Pinch a fold of skin. The thigh has less subcutaneous fat than the abdomen in most patients, so the pinch may be smaller.
5. Insert the needle at a 90-degree angle. Inject as described above.
6. The thigh is more vascular than the abdomen, so minor bleeding is more common. Apply pressure for 30-60 seconds if you see blood.

Upper arm (requires assistance for most patients):

1. The patient sits or stands with the arm relaxed and hanging at the side.
2. The person giving the injection stands behind the patient and locates the triceps muscle (back of the upper arm).
3. Clean the site with an alcohol swab.
4. Pinch a fold of skin in the middle of the triceps region.
5. Insert the needle at a 90-degree angle and inject as described above.
6. Patients often report that the upper arm is the least painful site, possibly because there are fewer nerve endings in the triceps region.

Common mistakes across all sites:

• Injecting through clothing (always inject into bare skin).
• Reusing needles (every needle should be new and sterile).
• Injecting cold medication straight from the fridge (let it reach room temperature for 15-30 minutes to reduce pain).
• Rubbing the injection site afterward (this can cause bruising and may push medication back out through the needle track).

FAQ

Can you inject semaglutide in the buttocks? No. The buttocks are not an FDA-approved injection site for semaglutide. The approved sites are abdomen, thigh, and upper arm only. The buttocks have a thicker subcutaneous layer, which would alter absorption kinetics in ways that haven't been studied in clinical trials.

Does it matter which side of the abdomen you inject? No. Left and right abdomen have equivalent absorption. What matters is rotating within the abdomen to avoid hitting the same spot repeatedly. Many patients alternate left and right weekly, which is fine as long as you also rotate up and down.

Can you inject semaglutide in the same spot every week? You shouldn't. Injecting in the same spot repeatedly causes lipohypertrophy (thickened tissue) that reduces absorption by 20-31%. Rotate to a different spot at least 1 inch away from last week's injection.

Which injection site hurts the least? Most patients report the abdomen is the least painful, followed by the upper arm, then the thigh. Pain varies based on individual nerve distribution, but the abdomen generally has the thickest subcutaneous fat layer, which cushions the needle.

Can you switch injection sites every week? Yes, the manufacturer says you may switch sites, but it's not required. Many patients experience more consistent drug levels by staying in one site (like the abdomen) and rotating within it. Switching sites weekly can cause slight variations in absorption timing.

What happens if you inject semaglutide into muscle? Intramuscular injection causes faster absorption than subcutaneous injection, which can lead to higher peak drug levels and more intense side effects. In diabetic patients on insulin, it increases hypoglycemia risk. If you suspect you injected into muscle (unusual pain, bleeding, or rapid onset of nausea), contact your provider.

How far apart should semaglutide injections be? At least 1 inch from the previous injection site. Semaglutide disperses through subcutaneous tissue in roughly a 1-inch radius, so injecting closer than that overlaps the dispersion zones and doubles local drug exposure.

Can you inject semaglutide in the love handles? Yes. The love handles (lateral abdomen) are part of the approved abdominal injection zone. Many patients prefer this area because the subcutaneous fat layer is often thickest there.

Is the thigh or abdomen better for semaglutide? The abdomen absorbs slightly faster (peak at 51 hours vs. 62 hours for the thigh), but total drug exposure is equivalent. Most patients choose based on comfort and convenience. The abdomen is easier to reach and has more surface area for rotation.

Do you pinch the skin when injecting semaglutide? Yes. Pinching a fold of skin lifts the subcutaneous fat away from the muscle, reducing the risk of intramuscular injection. The pinch should be released after the needle is inserted but before you push the plunger.

Can you inject semaglutide through a tattoo? The manufacturer says yes, but many clinicians recommend avoiding heavily tattooed areas because ink particles may interfere with drug dispersion. If you do inject through a tattoo, rotate away from that spot more frequently.

What if you see blood after injecting semaglutide? Minor bleeding is normal, especially in the thigh (which is more vascular). Apply gentle pressure with a clean gauze pad for 30-60 seconds. If bleeding doesn't stop after 2 minutes or if you develop a large bruise, contact your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Mayo Clinic Proceedings. 2016.
4. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Diabetes Care. 2010.
5. Buckley ST et al. Clinical Pharmacokinetics and Pharmacodynamics of Semaglutide. Clinical Pharmacokinetics. 2018.
6. Hirsch LJ et al. Comparative Glycemic Control, Safety and Patient Ratings for a New 4 mm × 32G Insulin Pen Needle. Diabetes Technology & Therapeutics. 2019.
7. Frid A et al. Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices. Mayo Clinic Proceedings. 2016.
8. Matfin G et al. Patient Perspectives on GLP-1 Receptor Agonist Therapies: A Systematic Review. Diabetes Therapy. 2020.
9. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
10. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
11. American Diabetes Association. Insulin Administration Standards of Care. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. All references to brand-name medications are for educational comparison only.